• Satellos Bioscience changed BASECAMP's primary efficacy endpoint to MRI-measured vastus lateralis fat fraction following FDA interactions.
• MRI fat fraction could support accelerated approval of forazapadin, with clinical data informing future regulatory discussions.
• BASECAMP enrolled 53 ambulatory boys aged 7-9 in a randomized, placebo-controlled Phase 2 trial.
• Topline results expected in Q1 2027 will focus on the 12-week fat fraction comparison against placebo.
• TRAILHEAD interim data showed a mean fat fraction reduction of 3.7 percentage points at five months across four participants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.